Jocasta Neuroscience, a pre-clinical biotech developing neurodegenerative disease therapies, raised a $35 million Series A, CEO Albert Agro tells Axios Pro exclusively.
Why it matters: Proceeds will help support its lead compound through a Phase 1 trial, after which Jocasta could seek Big Pharma partnerships, Agro says.
